Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.

NCT Number	NCT07664397
Lead Sponsor	Robert Flavell, MD, PhD Collaborators: Kyntra Bio, Fortis Therapeutics, Inc.
Conditions	Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor Neoplasms, Advanced Solid Tumor, Bladder Neoplasm +4 more
Enrollment	40 participants
Start Date	2026-08-01
Primary Completion	2029-09-30 (estimated)
Study Completion	2029-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-24